TY - JOUR T1 - Role of a <em>CYP17</em> Promoter Polymorphism for Familial Prostate Cancer Risk in Germany JF - Anticancer Research JO - Anticancer Res SP - 1303 LP - 1307 VL - 25 IS - 2B AU - ZORICA VESOVIC AU - KATHLEEN HERKOMMER AU - WALTHER VOGEL AU - THOMAS PAISS AU - CHRISTIANE MAIER Y1 - 2005/03/01 UR - http://ar.iiarjournals.org/content/25/2B/1303.abstract N2 - Background: A thymidine to cytosine transition (designated A2 variant) in the promoter region of CYP17 has previously been associated with a familial history of prostate cancer in North American families. The purpose of the present study was to determine whether this correlation could be replicated in a European population. Materials and Methods: Case-control comparisons were performed by modelling a dominant (A1/A2 + A2/A2 vs. A1/A1) and a recessive (A2/A2 vs. A1/A2 + A1/A1) effect of the promoter modification. Results: An insignificant overrepresentation of homozygous carriers of the A2 allele (recessive effect) was found in sporadic cases, as compared to controls. However, the A2 variant was not related to familial disease. Conclusion: Our results do not suggest a role of CYP17 as a high-risk susceptibility gene for familial prostate cancer, nor as a modifier for the disease risk in the European population. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -